Oryzon Genomics, a CataloniaBio & HealthTech member, announced the successful closure of the subscription of a capital increase of 13 million euros through ordinary shares. The offering included corporate investors specialized in healthcare and life sciences from the USA and Europe.
On the other hand, the biopharmaceutical company started the inclusion of the first patient in a Phase IIa clinical trial with Iadademstat (ORY-1001) in elderly Acute Myeloid Leukemia (AML). The study named ALICE (AML trial with LSD1i in Combination with azacitidine in the Elderly) is conducted at two Spanish hospitals, La Fe in Valencia and Vall d'Hebron in Barcelona.
Founded in 2000 in Barcelona, Oryzon is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics.
Photo: Carlos Buesa, co-founder and CEO of Oryzon
Comments